Centogene NV rises on extended genetic testing pact with Takeda

Crown LiquidationCo NV in liquidatie

11/04/2023 12:34

** U.S.-listed shares of Germany-based diagnostic and pharma
company Centogene N.V.  CNTG.O  rise 15.5% to 75 cents premarket
    ** Co extended partnership with Takeda Pharmaceutical
Company Limited  4502.T ,  TAK.N  to provide diagnosis to
patients with Lysosomal Storage Disorders (LSDs) 
    ** LSDs are inherited metabolic diseases that can lead to
dysfunction of organs
    ** Under the renewed, one-year partnership pact, CNTG will 
continue to provide Takeda with access to genetic testing
    ** The collaboration provides access to CNTG's Bio/Databank
that integrates patient-consented data, including clinical
information, health records, genetic insights, biomarkers and
patient-recorded outcomes 
    ** YTD, CNTG's U.S.-listed stock down ~30%, as of Monday's
close 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))